Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (2625)	7/29/1999 11:09:00 PM
From: Larry Brubaker	Respond to of 10293

Dale, those look like pretty good terms to me. Offering the warrants at a premium provides an incentive for the price to go up. From the little bit you posted, looks more like a long than a short candidate.

To: BDR who wrote (2625)	7/30/1999 8:52:00 AM
From: lindend	Respond to of 10293

Watch out for ENMD....this one burned me badly already.

To: BDR who wrote (2625)	7/30/1999 11:06:00 AM
From: Marconi	Respond to of 10293

Hello Mr. Russell: ENMD Although they are independent now, the abstracts from their research earlier this year looked reasonable and hold future promise. Only time and efforts will resolve whether they have something or not. --They do seem to have a supply of protein from yeast in sufficient quantities for medical testing. That is important. ---Their tests looked promising, but are early stage, too. -- No hints of yeast sensitivity related side reactions. ENMD seems to be at an appropriate stage of development and obtaining appropriate results for their compound. It is far too early to expect commercial success or failure. I had considered shorting prior to their going independent and prior to the abstracts published at the time they separated from their cash cow. Now I would not. The stock seems to be in a trading range, but I would only do that very short term--weeks at most. There is too much risk of news swinging the stock one way or the other. ENMD has raised reasonable resources to continue to investigate their compounds. I would be cautious about calling success or failure at this point--it is too early to tell, and they have yet to pave the way one way or the other. I think they are on track to test and evaluate whether they have a clinically useful compound or not. One possible touchpoint. I would keep an eye out for individual docs publishing an abstract on compassionate use of the compound in terminal cases where all other protocols were exhausted and ENMD;s compound was tried. That is about the earliest clinical effect that can be estimated, but should be considered anecdotal, not clinical study. With a pure enough compound satisfying FDA production requirements, they are in a position to do this. I am not following ENMD anywhere near closely enough to keep tabs on such activity. If you do, please let us know. Best regards, m